A Phase 1 Randomized Blinded Single Dose Comparison of the Safety and Pharmacokinetics of SYN060 Compared to Adalimumab (Humira) From North American and European Sources in Healthy Adult Subjects

Trial Profile

A Phase 1 Randomized Blinded Single Dose Comparison of the Safety and Pharmacokinetics of SYN060 Compared to Adalimumab (Humira) From North American and European Sources in Healthy Adult Subjects

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs SYN-060 (Primary) ; Adalimumab
  • Indications Autoimmune disorders; Bone disorders; Cancer
  • Focus Pharmacokinetics
  • Sponsors Synermore Biologics
  • Most Recent Events

    • 28 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top